[
  {
    "question": "Alzheimer\u2019s Dementia, what is the most common symptom",
    "option_a": "apathy",
    "option_b": "Delusion",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Alzheimer\u2019s dementia is a common neurodegenerative disorder typically defined by progressive memory loss. In addition to cognitive decline, a range of neuropsychiatric symptoms can develop; among these, apathy is frequently observed as one of the most common behavioral manifestations. Alzheimer\u2019s is characterized by the accumulation of beta\u2010amyloid plaques and neurofibrillary tangles (tau protein aggregates). Disruption of fronto\u2013subcortical circuits, particularly affecting areas like the anterior cingulate cortex, is thought to contribute to the development of apathy. Clinically, while memory impairment is the hallmark of early Alzheimer\u2019s, apathy emerges as a common and significant neuropsychiatric symptom. It is reflected in diminished motivation and reduced goal\u2010directed behavior, and is more commonly observed than delusions in many patients with Alzheimer\u2019s. Differentiating apathy from depression is key, as both can present with reduced activity. A detailed neuropsychiatric evaluation along with cognitive testing is used. Differential diagnoses include major depressive disorder and other dementias with behavioral disturbances, such as frontotemporal dementia. Management is primarily symptomatic. Cholinesterase inhibitors (e.g., donepezil, rivastigmine) and memantine are first-line agents for cognitive symptoms. For apathy, non-pharmacological interventions (like structured activities and behavioral therapies) are preferred; pharmacological treatments may be considered on a case-by-case basis, with careful consideration in pregnant or breastfeeding women due to potential medication risks. Option A (Apathy) is correct in the context of neuropsychiatric symptoms seen in Alzheimer\u2019s disease. Option B (Delusion) is less common as an early neuropsychiatric manifestation in Alzheimer\u2019s, making apathy the more frequent and characteristic symptom in this context. \u2022 Apathy is one of the most common behavioral symptoms in Alzheimer\u2019s and may be under-recognized.  \u2022 Distinguishing apathy from depression is essential for appropriate management. Recent studies consistently highlight apathy as a prevalent neuropsychiatric symptom in Alzheimer\u2019s disease. Updated diagnostic criteria and research are increasingly focused on optimal management strategies for neuropsychiatric aspects of dementia.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Alzheimer\u2019s Dementia with the gene mutation related to earlier onset. No PRESLIN in the choices",
    "option_a": "APP",
    "option_b": "APO.B",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Early-onset Alzheimer's dementia, which typically presents before the age of 65, is often linked to autosomal dominant gene mutations. The mutations in genes such as APP (amyloid precursor protein) are well established in familial cases. Mutations in the APP gene lead to altered processing of the amyloid precursor protein, resulting in the abnormal accumulation of beta-amyloid peptides. This accelerates plaque formation and neuronal injury. In familial early-onset Alzheimer\u2019s, other mutations like those in the presenilin-1 (PSEN1) and presenilin-2 (PSEN2) genes also play significant roles, but in this question, only the APP mutation is presented as an option. Patients with APP mutations tend to present with Alzheimer\u2019s symptoms at an earlier age, with rapid progression of memory impairment and other cognitive deficits. Recognizing a genetic predisposition helps in early diagnosis and family counseling. Diagnosis involves detailed family history, clinical evaluation, and when indicated, genetic testing for mutations in APP, PSEN1, and PSEN2. Differential diagnoses include other forms of dementia like frontotemporal dementia; however, the presence of a known mutation supports the diagnosis of early-onset Alzheimer\u2019s. Management remains supportive with cholinesterase inhibitors and memantine. Genetic counseling is critical for familial cases. In pregnant or lactating patients with a family history, the decision to initiate treatment is based on careful consideration of risks versus benefits, with close monitoring and an interdisciplinary approach. Option A (APP) is correct because APP gene mutations are one of the known causes of early-onset familial Alzheimer\u2019s disease. Option B (APO.B) is incorrect, as the APOE gene (particularly the \u03b54 allele) is associated with increased risk for late-onset Alzheimer\u2019s and is not typically the cause of early-onset familial cases. \u2022 Only a small percentage of Alzheimer\u2019s cases are familial, with APP, PSEN1, and PSEN2 mutations being the primary culprits in early-onset forms.  \u2022 A family history of early cognitive decline should prompt consideration of genetic testing. Current research in early-onset Alzheimer\u2019s emphasizes the importance of genetic screening and counseling. Emerging therapies targeting amyloid processing are under investigation, but management remains largely supportive at this time.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "A patient with behavioral changes is sent to psychiatry initially then neurology",
    "option_a": "??",
    "option_b": "represents a diagnosis consistent with the described clinical scenario, most likely behavioral variant frontotemporal dementia (bvFTD). Other options (not provided) might include primary psychiatric disorders or other neurodegenerative conditions. The scenario is classic for bvFTD, which explains the transition from psychiatric to neurological evaluation, thereby supporting Option B.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Dementia",
    "explanation": "Patients who present with prominent behavioral changes that initially lead them to psychiatric care are often later found to have an underlying neurological disorder. One of the most common examples is behavioral variant frontotemporal dementia (bvFTD), which primarily affects personality and behavior. bvFTD is characterized by degeneration of the frontal and temporal lobes, regions critical for behavior, emotion regulation, and executive function. The neurodegeneration results in disinhibition, apathy, compulsivity, and executive dysfunction. The classic misdiagnosis as a psychiatric disorder occurs because many of these symptoms overlap with primary psychiatric illnesses. Patients with bvFTD commonly present with marked changes in personality, social behavior, and executive function, often leading to an initial referral to psychiatry. As the disease progresses, neurological signs become more evident, leading to a neurology referral. This clinical evolution is a key indicator of an underlying neurodegenerative process rather than a primary psychiatric disorder. A detailed history and neuropsychological testing, along with neuroimaging (MRI or PET scan), are crucial for differentiating bvFTD from psychiatric conditions such as late-onset bipolar disorder or major depressive disorder. Biomarkers and clinical criteria (e.g., revised International bvFTD criteria) also play important roles in diagnosis. There is currently no disease-modifying therapy for bvFTD. Management focuses on symptomatic treatment and behavioral interventions. SSRIs may be used to manage behavioral symptoms, and non-pharmacological therapies including structured behavioral interventions are key. In pregnant or lactating patients, the risks and benefits of any psychotropic medication must be carefully weighed, with a preference for interventions with a more established safety profile. Given that the marked answer is B, the assumption is that Option B represents a diagnosis consistent with the described clinical scenario, most likely behavioral variant frontotemporal dementia (bvFTD). Other options (not provided) might include primary psychiatric disorders or other neurodegenerative conditions. The scenario is classic for bvFTD, which explains the transition from psychiatric to neurological evaluation, thereby supporting Option B. \u2022 Behavioral changes with early onset and prominent personality alterations should prompt consideration of bvFTD.  \u2022 Misdiagnosis as a primary psychiatric disorder is common; thus, neurological re-evaluation is essential when the clinical course is atypical. Recent guideline updates and research emphasize the importance of early identification of bvFTD using neuroimaging and clinical criteria. There is ongoing research into tailored symptomatic treatments, though currently management remains supportive and centered on quality-of-life improvements.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Patient has impaired fluency and repetition but intact comprehension, where is the localization?",
    "option_a": "Frontoparietal operculum",
    "option_b": "Inferior perisylvian",
    "option_c": "Parietotemporal perisylvian",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "This question describes a classic language disorder where speech production is impaired but comprehension remains relatively intact \u2013 a pattern seen in Broca's aphasia. Broca's aphasia is characterized by nonfluent, effortful speech with impaired repetition, yet patients typically understand language well. Broca's aphasia is most commonly due to a lesion in the dominant hemisphere\u2019s inferior frontal gyrus \u2013 an area often anatomically identified as the frontoparietal operculum. Damage here (typically from stroke, trauma, or tumor) disrupts the language circuit responsible for fluent, grammatically correct speech and repetition. Although the term 'inferior perisylvian' might generally refer to regions surrounding the Sylvian fissure, it does not specifically pinpoint Broca's area as accurately as the frontoparietal operculum does. Patients with lesions in Broca's area exhibit halting, agrammatic, and effortful speech, along with difficulty in repeating phrases. Their receptive language, mediated by Wernicke\u2019s area, is largely preserved. This dissociation is often confirmed through bedside language assessments and formal aphasia batteries. Diagnosis is based on clinical language assessment and neuroimaging (CT/MRI) to localize the lesion. Differential diagnoses include conduction aphasia (which shows fluent speech but disproportionately impaired repetition) and transcortical motor aphasia. Detailed language testing helps in differentiating these conditions. Management of Broca's aphasia includes addressing the underlying cause (e.g., thrombolysis for acute ischemic stroke), along with early initiation of speech and language therapy. In addition, supportive therapies and reeducation are important. For pregnant or lactating patients, any pharmacological interventions (like antithrombotics in stroke) need to be carefully chosen based on safety profiles, and speech therapy remains the cornerstone of rehabilitation. Option A, 'Frontoparietal operculum', accurately localizes Broca's area and is consistent with the clinical syndrome described. Option B, 'Inferior perisylvian', is less specific and can include a broader region that may be responsible for other language functions (such as repetition deficits seen in conduction aphasia). Option C (Parietotemporal perisylvian) is more aligned with Wernicke\u2019s area and would be associated with fluent aphasia with impaired comprehension. The marked answer (B) is therefore not the best fit. \u2022 Broca\u2019s aphasia: nonfluent speech with impaired repetition and relatively preserved comprehension is a hallmark. \u2022 Localization to the left inferior frontal gyrus (especially the pars opercularis/triangularis) is key in making the diagnosis. Recent neuroimaging studies have refined our understanding of language networks, confirming that lesions in the frontoparietal operculum (specifically the inferior frontal gyrus) are strongly associated with nonfluent aphasia. Current stroke guidelines emphasize early localization and targeted rehabilitation for optimal recovery.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "What is the suspected symptom in patient with corpus callosum lesion?",
    "option_a": "Alexia without agraphia",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Lesions of the corpus callosum can cause disconnection syndromes, which occur when the integration of information between the two hemispheres is disrupted. One classical disconnection syndrome is alexia without agraphia, wherein the patient loses the ability to read despite retaining the ability to write. Alexia without agraphia typically results from a lesion in the splenium of the corpus callosum (often combined with involvement of the left occipital lobe). The splenium normally relays visual information from the intact right visual cortex to the language-dominant left hemisphere. When this communication is disrupted, visual input cannot be adequately processed for reading, even though writing remains intact. Patients with alexia without agraphia may complain that they suddenly cannot read, despite their ability to write and understand spoken language. This disconnection between visual input and language production is pathognomonic for the syndrome. Diagnosis involves neuroimaging (MRI preferred), which reveals lesions in the splenium of the corpus callosum, often in conjunction with left occipital lobe involvement. Differential diagnoses include visual agnosia and other forms of aphasia; however, the preservation of writing despite impaired reading is a distinguishing clue. Management involves treating the underlying cause (for instance, managing a stroke, demyelinating process, or tumor). Rehabilitation strategies focusing on visual and language integration are employed. In pregnant or lactating patients, careful consideration of imaging (MRI without contrast when possible) and medications (avoiding teratogenic agents) is warranted. Option A, 'Alexia without agraphia', accurately describes a classic symptom resulting from a lesion in the splenium of the corpus callosum (especially when combined with left occipital damage). Without other options provided, this answer is the best match for the question, and the marked answer is correct. \u2022 Alexia without agraphia is a classic disconnection syndrome that highlights the need for intact interhemispheric communication for reading. \u2022 The syndrome is most often seen when the splenium of the corpus callosum and adjacent left occipital lobe are compromised. Recent literature has expanded on disconnection syndromes by detailing precise neuroanatomical correlates using advanced neuroimaging. The understanding of corpus callosum lesions has increased, reinforcing the association between splenial damage and specific reading deficits.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Elderly patient presented with fluctuating levels of consciousness, which of the following should be done?",
    "option_a": "Metabolic panel screen",
    "option_b": "?",
    "option_c": "?",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "In elderly patients with fluctuating levels of consciousness, it is critical to rapidly identify potentially reversible metabolic or systemic causes. A metabolic panel is a fundamental screening tool that evaluates various biochemical parameters which may underlie such an altered mental state. Fluctuating consciousness can be triggered by metabolic derangements such as electrolyte imbalances (e.g., hyponatremia), hypoglycemia or hyperglycemia, renal or hepatic dysfunction, and other systemic disturbances. The pathophysiology often involves cerebral dysfunction secondary to metabolic insults. Elderly patients are particularly vulnerable to metabolic imbalances due to comorbidities and polypharmacy. They may present with confusion, disorientation, and variable alertness. A metabolic panel helps in detecting these abnormalities early. Initial evaluation of fluctuating consciousness in the elderly should include a comprehensive metabolic panel, complete blood count, urinalysis, and in some cases, toxicology screening. Differential diagnoses include infections (e.g., urinary tract infections, sepsis), intoxications, and neurological events like stroke. Laboratory tests help differentiate these conditions. The tiered approach involves: First, rapidly identifying and correcting any metabolic or electrolyte abnormalities; second, addressing any underlying systemic conditions (infection, organ failure); and third, providing supportive care. In pregnant or lactating patients, medication choices and fluid management must be made with caution, ensuring that treatments are safe for both the mother and child. Option A, 'Metabolic panel screen', is the correct initial step in workup since metabolic disturbances are common and potentially reversible causes of fluctuating consciousness in the elderly. The other options, albeit not provided, would likely address secondary investigations or are less immediately useful. \u2022 Always consider metabolic causes in elderly patients with altered mental status. \u2022 Early detection via laboratory screening can significantly improve outcomes by allowing for prompt correction of reversible conditions. The latest guidelines emphasize that a thorough metabolic workup is mandatory in the emergency evaluation of elderly patients with fluctuating levels of consciousness. Recent research supports improved morbidity outcomes with early identification and treatment of metabolic derangements.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "what helps differentiate AD from FTD?",
    "option_a": "Anterograde memory loss",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Differentiating Alzheimer\u2019s disease (AD) from frontotemporal dementia (FTD) is crucial as they have distinct clinical presentations. AD is characterized primarily by memory impairment, specifically anterograde memory loss, whereas FTD typically presents with predominant changes in personality, behavior, or language with relative sparing of early memory function. In AD, neuropathological changes such as beta-amyloid plaque deposition and neurofibrillary tangles primarily affect the medial temporal lobe structures (including the hippocampus), leading to prominent deficits in forming new memories. In contrast, FTD involves degeneration of the frontal and anterior temporal lobes, affecting behavior, executive function, and language but initially sparing episodic memory. Clinically, patients with AD present with early anterograde amnesia \u2013 difficulty forming new memories \u2013 which is the hallmark. FTD patients, however, may display marked personality changes, impulsivity, or aphasic symptoms without significant early memory loss. This clinical distinction is essential for diagnosis and management. Diagnosis relies on detailed neuropsychological testing and neuroimaging (MRI, PET) to assess the pattern of atrophy and functional changes. Differential diagnoses include other causes of dementia such as vascular dementia or Lewy body dementia, which have their own distinct clinical and imaging features. For AD, first-line management includes cholinesterase inhibitors (e.g., donepezil) and NMDA receptor antagonists (e.g., memantine) along with non-pharmacologic support like cognitive rehabilitation. FTD management is more supportive, as these patients generally do not respond to cholinesterase inhibitors\u2014instead, therapies may focus on behavioral management and speech therapy. In pregnant or lactating patients, medication decisions must be individualized with a focus on safety; non-pharmacologic interventions and careful monitoring are emphasized. Option A, 'Anterograde memory loss', is correct since early impairment in forming new memories is a signature feature of AD and is typically absent or less pronounced in early FTD. Other options, though not provided here, would likely address features more characteristic of FTD (e.g., personality change, disinhibition) and thus help in differentiation. \u2022 In AD, early anterograde amnesia is a key diagnostic clue. \u2022 FTD generally spares early memory function but shows marked behavioral or language changes. Emerging research, including biomarkers and advanced neuroimaging, continues to refine the differential diagnosis between AD and FTD. Updated clinical guidelines underscore the importance of neuropsychological profiles in differentiating these dementias for proper management.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "one year of progressive apathy , memory loss, what is it most likely",
    "option_a": "AD",
    "option_b": "FTD",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Alzheimer\u2019s disease (AD) is a neurodegenerative disorder characterized primarily by progressive memory loss, along with other cognitive deficits. Although apathy can occur in several dementias, the early and prominent memory impairment seen in AD is a key diagnostic clue, distinguishing it from conditions such as frontotemporal dementia (FTD), where behavioral changes occur early. AD is driven by the accumulation of beta-amyloid plaques and tau neurofibrillary tangles. These pathological changes lead to synaptic dysfunction, neuronal loss, and subsequent brain atrophy, particularly in the hippocampus and cortical regions that govern memory and cognition. Neuroinflammation also plays an important role in the disease progression. Patients with AD typically exhibit a gradual decline in short-term memory, difficulty with recent events, and impaired executive functions. Apathy is common, though not the most specific feature. In contrast, FTD generally features early personality and behavioral changes with relative preservation of memory in the initial stages. Diagnosis is primarily clinical, based on neuropsychological testing and patient history. Neuroimaging (MRI or CT) may show medial temporal lobe atrophy. Differential diagnoses include frontotemporal dementia (more behavioral changes, less memory impairment early on), vascular dementia (stepwise decline with focal deficits), and Lewy body dementia (early hallucinations and fluctuating cognition). First-line management includes cholinesterase inhibitors (donepezil, rivastigmine, galantamine) to slow cognitive decline, with memantine considered in moderate to severe stages. Non-pharmacologic interventions like cognitive rehabilitation, structured routines, and caregiver support are important. In pregnancy or lactation\u2014though rare in AD cases\u2014use of these medications requires careful risk\u2013benefit assessment as safety data are limited. Option A (Alzheimer\u2019s disease) is correct because the combination of progressive memory loss with apathy fits the classic presentation of AD. Option B (Frontotemporal dementia) is less likely because its early presentation is dominated by marked behavioral and personality changes rather than memory loss. 1. Early memory impairment is the hallmark of AD. 2. Apathy can be seen in several dementias, but its presence alongside memory deficits strongly supports AD. 3. AD remains the most common cause of dementia in the elderly. Recent advances in biomarker research (CSF tau and beta-amyloid levels, PET imaging) have improved early diagnosis. Ongoing studies are investigating anti-amyloid and tau-targeted therapies, although current treatment remains symptomatic.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "choloinssterase inhibitors most useful for apathy",
    "option_a": "(Cholinesterase inhibitors) is correct as they target the cholinergic deficit implicated in apathy among AD patients. Option B (Antidepressants) primarily treat mood symptoms and are less effective for apathy when depressive symptoms are absent. Option C (Antipsychotics) can worsen apathy due to sedative effects and increase the risk of adverse events. Option D (Psychostimulants) may improve apathy but are considered second",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "(NMDA receptor antagonists) like memantine have limited evidence for managing apathy directly.",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Cholinesterase inhibitors (ChEIs) increase synaptic acetylcholine and are used primarily in Alzheimer\u2019s disease. They address disturbances in cholinergic neurotransmission believed to contribute not only to memory impairment but also to behavioral symptoms such as apathy. In Alzheimer\u2019s disease, reduced cholinergic activity is a major component of the pathophysiological process. By inhibiting the enzyme acetylcholinesterase, these drugs enhance cholinergic transmission, potentially improving cognitive and behavioral symptoms, including apathy. Apathy in AD, while multifactorial, is partly related to a hypocholinergic state. ChEIs can modestly improve motivation and cognitive function, thereby alleviating some aspects of apathy. This is especially relevant when the apathy is not due to depression but to neuronal dysfunction. When evaluating apathy, it is important to distinguish it from depression. A comprehensive neuropsychiatric assessment helps to evaluate cognitive impairment, mood, and executive function. The response to ChEIs further supports a cholinergic deficiency underlying the symptom. First-line treatment for apathy in the context of AD involves cholinesterase inhibitors (such as donepezil, rivastigmine, or galantamine). Second-line options, like psychostimulants (e.g., methylphenidate), may be considered if there is an inadequate response; however, they have a less favorable side effect profile. In pregnancy or lactation, these medications are generally avoided or used only if the potential benefits outweigh the risks due to limited safety data. Option A (Cholinesterase inhibitors) is correct as they target the cholinergic deficit implicated in apathy among AD patients. Option B (Antidepressants) primarily treat mood symptoms and are less effective for apathy when depressive symptoms are absent. Option C (Antipsychotics) can worsen apathy due to sedative effects and increase the risk of adverse events. Option D (Psychostimulants) may improve apathy but are considered second-line due to side effects. Option E (NMDA receptor antagonists) like memantine have limited evidence for managing apathy directly. 1. Always differentiate apathy from depression in dementia management. 2. Cholinesterase inhibitors remain the cornerstone of symptomatic therapy in AD. 3. Adjust treatment strategies for special populations, including pregnant or lactating women, due to limited safety data. Recent randomized controlled studies demonstrate modest improvements in apathy scores with ChEIs in AD patients. Ongoing research is evaluating combination approaches targeting multiple neurotransmitter systems to further address behavioral symptoms.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "elderly man came with his wife, his wife is complaining in the past year he husban was acting out his dreams amd kicking her and he has been seeing vivid visual hallucinations and was at periods acting as if he hes delerium but all of delerium workup was negative what is the most likely dx?",
    "option_a": "LBD",
    "option_b": "AD",
    "option_c": "CBD",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Lewy Body Dementia (LBD) is characterized by cognitive fluctuations, visual hallucinations, and parkinsonian features along with REM sleep behavior disorder. The described history\u2014dream enactment behavior, vivid visual hallucinations, and episodes mimicking delirium\u2014strongly supports a diagnosis of LBD. LBD involves the accumulation of alpha-synuclein in the form of Lewy bodies within neurons, especially affecting areas involved in cognition, visual processing, and motor control. REM sleep behavior disorder arises from degeneration in brainstem regions that regulate the normal atonia of REM sleep. The patient\u2019s symptoms, including acting out dreams (REM sleep behavior disorder), visual hallucinations, and fluctuating cognition without metabolic evidence of delirium, align with the typical presentation of LBD. In contrast, Alzheimer\u2019s disease usually does not present with early, prominent visual hallucinations or REM sleep behavior disorder. Diagnostic evaluation includes thorough clinical assessment, neuropsychological testing, and supportive imaging (e.g., DAT-SPECT to assess dopaminergic deficits). Differential diagnoses include Alzheimer\u2019s disease (lacking prominent visual hallucinations), vascular dementia (stepwise decline with focal deficits), and delirium (acute onset with abnormal labs). Management involves the cautious use of cholinesterase inhibitors (e.g., rivastigmine) to help with cognitive fluctuations and hallucinations. Antipsychotics must be used with extreme caution because of severe sensitivity in LBD patients. In pregnant or lactating patients (a rare scenario in LBD), non-pharmacologic interventions are preferred due to limited safety data on these medications. Option A (LBD) is correct because the combination of REM sleep behavior disorder (acting out dreams), vivid visual hallucinations, and cognitive decline is most characteristic of Lewy Body Dementia. Option B (AD) is less likely because AD does not typically feature early visual hallucinations or REM sleep behavior disorder. Option C (CBD) or corticobasal degeneration typically presents with asymmetric motor findings and apraxia, which are not described here. 1. REM sleep behavior disorder is an early and important clue in diagnosing LBD. 2. Patients with LBD are extremely sensitive to antipsychotic medications. 3. Visual hallucinations coupled with cognitive fluctuations strongly favor LBD over AD. Current guidelines emphasize early recognition of LBD to avoid the use of contraindicated medications like typical antipsychotics. Advances in imaging (such as DAT-SPECT) and refined clinical criteria have improved diagnostic accuracy.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "70-year-old male with cognitive decline, ataxia and startle response. Diagnosis:",
    "option_a": "",
    "option_b": "",
    "option_c": "is correct because it encapsulates the diagnosis of a neurogenetic disorder that presents with the triad of cognitive decline, ataxia, and an exaggerated startle response. Option A would typically describe a common neurodegenerative dementia without the prominent startle feature; Option B might represent a pure cerebellar syndrome without cognitive impairment; Option D could imply non",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Dementia",
    "explanation": "The triad of cognitive decline, ataxia, and an exaggerated startle response is unusual and suggests a neurodegenerative condition that involves multiple neural systems. Such a constellation is classically associated with certain neurogenetic disorders, including forms of progressive myoclonic epilepsies or hereditary ataxias with myoclonic features. In neurogenetic disorders that present with this triad, genetic mutations lead to dysfunction in neuronal circuits regulating cognition, cerebellar coordination, and motor control (including exaggerated startle mechanisms). Abnormal protein accumulations or metabolic disturbances can affect both cortical and subcortical areas, resulting in cognitive decline, ataxia, and abnormal reflex responses. The presence of cognitive decline along with ataxia and an exaggerated startle or myoclonic response in a 70\u2010year\u2010old patient narrows the differential. Although many progressive myoclonic epilepsies present earlier in life, late-onset variants or hereditary ataxias with cognitive involvement are recognized, supporting a neurogenetic etiology as opposed to more common degenerative dementias. A thorough workup including detailed family history, genetic testing, neuroimaging (MRI), and electrophysiological studies (EEG) is critical for diagnosis. Differential diagnoses include Alzheimer\u2019s disease (which typically lacks prominent ataxia and startle features), normal pressure hydrocephalus (which presents with gait disturbance and cognitive decline but not an exaggerated startle response), and vascular dementia (often presenting with stepwise decline and focal deficits). Management is largely supportive. First-line therapy often focuses on symptomatic treatment with antiepileptic drugs (like valproate or levetiracetam) to manage myoclonus, while cognitive interventions and physical therapy help address cognitive decline and ataxia. In pregnant or lactating patients, antiepileptic choices must be carefully selected to minimize teratogenic risk (for example, avoiding valproate if possible and considering agents with better pregnancy safety profiles). Option C is correct because it encapsulates the diagnosis of a neurogenetic disorder that presents with the triad of cognitive decline, ataxia, and an exaggerated startle response. Option A would typically describe a common neurodegenerative dementia without the prominent startle feature; Option B might represent a pure cerebellar syndrome without cognitive impairment; Option D could imply non-genetic, acquired causes (e.g., normal pressure hydrocephalus) that do not exhibit the startle phenomenon. 1. An exaggerated startle response in a patient with cognitive decline is an uncommon finding and should prompt evaluation for neurogenetic disorders. 2. Always consider hereditary causes in atypical presentations even in older patients. 3. A comprehensive history including family history is essential in suspected neurogenetic disorders. Recent advances in genetic testing have improved the diagnosis of neurogenetic disorders presenting later in life. There is ongoing research to better characterize late-onset variants of progressive myoclonic epilepsies and hereditary ataxias, with an emphasis on tailored, multidisciplinary management approaches.",
    "exam_year": "2018",
    "exam_type": "Promotion"
  },
  {
    "question": "What is the second most common type of neurodegenerative dementia?",
    "option_a": "AD",
    "option_b": "LBD",
    "option_c": "FTD",
    "option_d": "Vascular dementia",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Dementia",
    "explanation": "Neurodegenerative dementias are a group of disorders characterized by progressive loss of neuronal structure and function. Alzheimer\u2019s disease (AD) is the most common form. When the term 'neurodegenerative' is strictly applied to disorders resulting from intrinsic degenerative processes (e.g., protein misfolding), vascular dementia is usually excluded because its pathology is primarily due to cerebrovascular events. Thus, among purely neurodegenerative dementias, Dementia with Lewy Bodies (LBD) is typically considered the second most common. LBD is characterized by the abnormal deposition of alpha\u2010synuclein protein aggregates (Lewy bodies) in cortical and subcortical regions. This leads to fluctuating cognitive impairment, visual hallucinations, and motor parkinsonian features. In contrast, AD is marked by amyloid plaques and neurofibrillary tangles, while vascular dementia stems from infarcts rather than intrinsic neuronal degeneration. Patients with LBD often present with fluctuating cognition, prominent visual hallucinations, and parkinsonism. Recognizing the disorder\u2019s neurobiology is key\u2014its degeneration is due to abnormal protein accumulation, not vascular insults. The clinical picture helps differentiate it from AD (where memory impairment predominates) or from vascular dementia (which may have a stepwise course). The evaluation of dementia includes history, neuropsychological testing, and neuroimaging (MRI or CT) to look for patterns of atrophy or infarction. Differentials include Alzheimer\u2019s disease, frontotemporal dementia, and vascular dementia. In LBD, supportive features include REM sleep behavior disorder and sensitivity to antipsychotics. Biomarkers like dopamine transporter (DAT) scans can also aid in differentiation. Management of LBD is symptomatic. First-line treatments include cholinesterase inhibitors (donepezil, rivastigmine) to improve cognition and stabilize behavior. Second-line management may involve cautious use of atypical antipsychotics for psychosis, keeping in mind severe sensitivity in LBD. In cases where patients are pregnant or lactating (rare in LBD due to age demographics), treatment options are limited and must be weighed carefully against potential risks. Nonpharmacologic therapies and supportive care remain important. Option A (AD) is the most common dementia, not the second most common neurodegenerative type. Option B (LBD) is correct for second most common neurodegenerative dementia when excluding vascular causes. Option C (FTD) is less prevalent and typically presents with early behavioral or language changes. Option D (Vascular dementia) is indeed common but is not considered a primary neurodegenerative condition because its etiology is vascular rather than degenerative. 1. Lewy body dementia frequently presents with visual hallucinations and fluctuating cognition. 2. Vascular dementia, although common, is not classified as a neurodegenerative condition. 3. Cholinesterase inhibitors remain a mainstay of symptomatic management in LBD. Recent research emphasizes the role of biomarkers (including DAT imaging and cerebrospinal fluid analysis) to improve diagnostic accuracy in LBD. Updated guidelines stress a cautious approach to antipsychotic use due to sensitivity and adverse effects, with an emphasis on individualized, symptomatic management.",
    "exam_year": "2018",
    "exam_type": "Promotion"
  },
  {
    "question": "Declarative memory with remembering past experience:",
    "option_a": "Episodic",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Declarative (explicit) memory refers to memories that can be consciously recalled, which is divided into episodic (personal experiences and events) and semantic (facts and general knowledge) memory. The question targets the concept of recalling past personal experiences. Episodic memory relies primarily on the medial temporal lobes, especially the hippocampus, and its surrounding cortical connections. Disruption in these regions (as seen in early Alzheimer\u2019s disease) leads to significant impairment in forming or retrieving autobiographical events. Patients with deficits in episodic memory often have difficulty recalling events from their own lives, a hallmark early finding in conditions like Alzheimer\u2019s disease. This contrasts with deficits in other memory types, such as procedural or semantic, where other brain circuits are involved. Assessment of memory involves neuropsychological testing that differentiates between episodic, semantic, and other memory types. Differential diagnoses include Alzheimer\u2019s disease (episodic impairment), semantic dementia, and other neurocognitive disorders. Detailed history and targeted cognitive tests help distinguish these. While this question deals with memory types rather than a treatable condition, the management of memory deficits in conditions like Alzheimer\u2019s disease involves early cognitive interventions, use of cholinesterase inhibitors (donepezil, rivastigmine) as first-line therapy, and memantine in moderate-severe stages. In pregnant or lactating patients, the use of such medications would require thorough risk\u2013benefit analysis with current guidelines hand in hand with nonpharmacologic interventions. Option A (Episodic) is correct because it specifically deals with the recall of personal experiences over time. The other options are either blank or not provided, and thus are not applicable. 1. Episodic memory is autobiographical and time-stamped, making it distinct from semantic memory. 2. Early impairment in episodic memory is often one of the first signs in Alzheimer\u2019s disease. 3. Neuropsychological testing is essential to differentiate memory subtypes. Current research emphasizes early detection of episodic memory impairment as a predictor of progression in Alzheimer\u2019s disease, with ongoing studies examining the protective effects of lifestyle modifications and early pharmacological interventions.",
    "exam_year": "2018",
    "exam_type": "Promotion"
  },
  {
    "question": "Donepezil mechanism of action:",
    "option_a": "Acetylcholine esterase inhibitor",
    "option_b": "Acetylcholine esterase agonist",
    "option_c": "NMDA antagonist",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Donepezil is a medication approved for the symptomatic treatment of Alzheimer\u2019s disease. It works by increasing the concentration of acetylcholine in the brain, which is a neurotransmitter that plays a critical role in learning and memory. In Alzheimer\u2019s disease, there is a reduction in cholinergic transmission due to degeneration of basal forebrain cholinergic neurons. Donepezil reversibly inhibits acetylcholinesterase, the enzyme responsible for the breakdown of acetylcholine, thereby enhancing cholinergic neurotransmission and partially compensating for the loss of cholinergic neurons. The use of donepezil can lead to modest improvements in cognitive function, memory, and overall daily functioning in patients with mild to moderate Alzheimer\u2019s disease. Common side effects include gastrointestinal distress, insomnia, and muscle cramps, which correlate with increased cholinergic activity. While the diagnosis of Alzheimer\u2019s disease is based on clinical criteria supported by imaging and biomarkers in some cases, donepezil is indicated after the diagnosis. Differential mechanisms include NMDA antagonism (used by memantine) which has a different role in neuroprotection. First-line management of mild to moderate Alzheimer\u2019s disease includes cholinesterase inhibitors like donepezil. In some patients with moderate to severe disease, memantine (an NMDA receptor antagonist) is added as a second-line therapy. In special populations such as pregnant or lactating women, the use of donepezil is not well studied; risk\u2013benefit discussions are mandatory and alternative management or deferring therapy might be considered. Option A (Acetylcholine esterase inhibitor) is correct as it accurately describes the mechanism of donepezil. Option B (Acetylcholine esterase agonist) is incorrect because donepezil does not activate the enzyme\u2014it inhibits its function. Option C (NMDA antagonist) is the mechanism of memantine, not donepezil. 1. Donepezil\u2019s inhibition of acetylcholinesterase leads to increased acetylcholine levels, which can help alleviate some symptoms of Alzheimer\u2019s disease. 2. Cholinesterase inhibitors are generally first-line for mild to moderate Alzheimer\u2019s disease. 3. Gastrointestinal side effects are common and may limit tolerability in some patients. Recent clinical trials continue to support the role of cholinesterase inhibitors in improving quality of life in Alzheimer\u2019s patients, though the benefits are modest. Research is ongoing into combination therapies and disease-modifying treatments, with current guidelines reinforcing individualized care plans based on patient characteristics and comorbidities.",
    "exam_year": "2018",
    "exam_type": "Promotion"
  },
  {
    "question": "A patient with a visual field defect, impaired reading, with intact writing. Picture of alexia without agraphia. Localization:",
    "option_a": "Splenium of corpus callosum",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Alexia without agraphia is a disconnection syndrome where a patient loses the ability to read despite intact writing skills. This syndrome arises because the visual input cannot reach the language processing areas in the dominant hemisphere, typically due to a lesion involving the splenium of the corpus callosum and the contralateral (usually left) occipital cortex. In alexia without agraphia, a lesion in the left occipital lobe causes a right homonymous hemianopia, while damage to the splenium of the corpus callosum prevents visual information from the intact right visual cortex from being transmitted to the language-dominant left hemisphere. This disconnection results in the inability to read, although the ability to write is preserved because language production centers remain intact. Patients typically present with a visual field defect (usually right-sided), impaired reading with preserved writing, and often complaints of difficulty recognizing words. The syndrome is classically associated with infarction in the territory of the left posterior cerebral artery, which supplies both the occipital region and the splenium. Diagnosis is based on clinical examination, neuropsychological testing, and neuroimaging. MRI is the modality of choice to identify infarcts in the left occipital lobe and splenium. Differential diagnoses include alexia with agraphia (when both reading and writing are impaired), aphasic disorders from left parietal or temporal lesions, and visual agnosia; careful neuroanatomical correlation on imaging helps differentiate these. Management focuses on addressing the underlying cause\u2014typically acute stroke management, which includes revascularization strategies in eligible patients and secondary prevention measures (antiplatelets, risk factor management). Rehabilitation techniques, including visual rehabilitation and compensatory strategies for reading, are important. In pregnant or lactating patients with stroke, guidelines advise modified risk\u2013benefit considerations with careful use of thrombolytics or anticoagulation as per current stroke management protocols. Option A (Splenium of corpus callosum) is correct because the lesion in this region, in conjunction with left occipital involvement, disrupts the transfer of visual information to language areas. Other options (if provided) might include isolated occipital or parietal lesions, which would not fully explain the disconnection syndrome leading to preserved writing with impaired reading. 1. Alexia without agraphia is a hallmark disconnection syndrome, typically due to a left occipital and splenial lesion. 2. Patients exhibit a specific deficit: inability to read while retaining the ability to write. 3. It is most commonly related to an infarction in the territory of the left posterior cerebral artery. Recent advances in neuroimaging have enhanced the ability to localize infarcts causing alexia without agraphia. The emphasis on early revascularization in acute stroke management has improved outcomes, and current guidelines underscore the importance of individualized rehabilitation strategies to address persistent deficits.",
    "exam_year": "2018",
    "exam_type": "Promotion"
  },
  {
    "question": "Balint syndrome. Which one of these clinical pictures is one of the presentations?",
    "option_a": "Simultagnosia",
    "option_b": "Acalculia",
    "option_c": "vivid hallucination",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Balint syndrome is a rare neuropsychological condition that occurs due to bilateral lesions in the parietal\u2013occipital regions. It is classically characterized by a triad: simultanagnosia (inability to perceive multiple objects simultaneously), optic ataxia (difficulty in visually guided reaching), and oculomotor apraxia (difficulty in voluntarily directing gaze). The syndrome arises from damage to the dorsal stream of visual processing, particularly affecting the posterior parietal lobes. This disrupts spatial awareness and integrated visual perception. The underlying causative lesions most often result from infarcts, trauma, or neurodegenerative processes affecting these regions. Recent studies emphasize the role of network disintegration within the visual and parietal systems as a key mechanism. Patients with Balint syndrome typically experience difficulties in reading, navigating complex visual scenes, or even grasping objects due to impaired visual integration. Simultanagnosia, the inability to appreciate more than one object at a time, is one of the hallmark symptoms that leads to frustrating visual confusion in real-world settings. The diagnosis is clinical, based on the identification of the syndrome\u2019s triad. Neuroimaging (CT or MRI) is used to identify bilateral parieto-occipital lesions. Differential diagnoses include unilateral visual neglect (typically after a single hemisphere lesion) and other visual processing disorders. Detailed neuropsychological testing can help delineate the deficits. There is no curative treatment for Balint syndrome; management is supportive and aims at rehabilitating visual and perceptual skills. Therapy may include occupational therapy and compensatory strategies. Management of the underlying cause (e.g., stroke, trauma) is essential. Pregnancy and lactation considerations are generally not applicable unless the underlying etiology (such as a stroke) requires specific management modifications. Option A (Simultanagnosia) is correct because it directly represents one of the classic features of Balint syndrome. Option B (Acalculia) refers to difficulty with mathematical calculations, not a typical feature. Option C (Vivid hallucination) is not a characteristic feature of Balint syndrome. 1. The triad of simultanagnosia, optic ataxia, and oculomotor apraxia is pathognomonic for Balint syndrome. 2. Bilateral parieto-occipital lesions are typically responsible for the syndrome. 3. The deficit is in the integration of visual information, not a primary visual loss. Recent research continues to explore rehabilitative strategies and neuroplasticity as potential areas for intervention. Advances in neuroimaging have improved our understanding of the network dysfunction underpinning the syndrome, although treatment remains largely symptomatic.",
    "exam_year": "2018",
    "exam_type": "Promotion"
  },
  {
    "question": "52-year-old women present with behavioral changes over the course of 2 years. Her concentration is decreasing making it difficult to accomplish her work and she does not care about her poor performance. She is eating more and has gained 25 pounds in 4 months. She is being charged at work related to telling inappropriate dirty jokes. She has stopped bathing and refuses to take care of her personal hygiene. On examination, she has grasp and palmo-mental reflex but no other abnormalities. Her MMSE is 29/30 but her clock drawing test was poor. What is the diagnosis?",
    "option_a": "Vascular dementia",
    "option_b": "FTD",
    "option_c": "NPH",
    "option_d": "Presenilin dementia",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Dementia",
    "explanation": "Frontotemporal dementia (FTD) is a neurodegenerative disorder noted for predominant changes in personality, behavior, and executive function rather than memory impairment, especially in its early stages. FTD involves progressive degeneration of the frontal and temporal lobes, often associated with abnormal protein accumulations such as tau or TDP-43. These molecular abnormalities lead to neuronal loss and atrophy particularly affecting the regions responsible for behavior and social conduct. The patient\u2019s presentation, including behavioral disinhibition (inappropriate jokes), apathy (lack of concern for performance), changes in eating behavior (increased appetite and weight gain), and presence of frontal release signs (grasp and palmo-mental reflexes), fits with the behavioral variant of FTD. Preserved scores on MMSE with poor performance on more complex tasks like clock drawing further support early executive dysfunction. Diagnosis involves a combination of clinical assessment, neuropsychological testing, and neuroimaging (MRI showing frontal lobe atrophy). Differential diagnoses include Alzheimer\u2019s disease (which typically presents with prominent memory impairment), vascular dementia (with a stepwise decline), and atypical presentations such as presenilin dementia (related to familial Alzheimer's disease). Currently, there is no disease-modifying treatment for FTD. Management is focused on symptomatic treatment, behavioral management, and supportive care. Selective serotonin reuptake inhibitors (SSRIs) and other mood stabilizers can be used to mitigate behavioral symptoms. In terms of non-pharmacologic management, cognitive rehabilitation and caregiver support are essential. In pregnancy and lactation, careful consideration is required when selecting psychiatric medications; SSRIs are generally considered safer but dosage and risk\u2013benefit discussions must be individualized. Option B (FTD) is correct because the clinical scenario (behavioral changes, executive dysfunction, preserved orientation/memory on MMSE but flawed complex tasks) is most characteristic of FTD. Option A (Vascular dementia) usually presents with stepwise deterioration. Option C (Normal Pressure Hydrocephalus) typically exhibits gait disturbances, urinary incontinence, and dementia, while Option D (Presenilin dementia) refers to familial Alzheimer\u2019s disease which doesn\u2019t fit the behavioral profile here. 1. Early behavioral changes and disinhibition are hallmarks of the behavioral variant of FTD. 2. Frontal release signs indicate frontal lobe involvement. 3. Neuroimaging typically reveals frontal and anterior temporal atrophy in FTD. Emerging research focuses on imaging biomarkers and the role of tau pathology in FTD. Therapeutic trials targeting protein aggregation are in progress, though current management remains symptomatic. Updated guidelines stress the importance of individualized care and the support of caregivers.",
    "exam_year": "2018",
    "exam_type": "Promotion"
  },
  {
    "question": "Cognitive fluctuation more common in:",
    "option_a": "DLB",
    "option_b": "AD",
    "option_c": "FTD",
    "option_d": "Vascular",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Dementia with Lewy bodies (DLB) is a neurodegenerative disorder characterized predominantly by fluctuating cognition, visual hallucinations, and parkinsonian motor symptoms. DLB is thought to result from the cortical deposition of alpha-synuclein proteins, leading to Lewy body formation. This disrupts neuronal communication and causes variable neurotransmitter imbalances, particularly affecting dopaminergic and cholinergic systems, which underlie cognitive fluctuations. Patients with DLB typically experience periods of marked cognitive impairment interspersed with relative clarity, along with recurrent visual hallucinations and motor symptoms similar to Parkinson\u2019s disease. These cognitive fluctuations differentiate DLB from other dementia types, where decline is generally more progressive and consistent. Diagnosis is clinical, supported by criteria that include the presence of fluctuating cognition, recurrent visual hallucinations, REM sleep behavior disorder, and parkinsonism. Differential diagnoses include Alzheimer\u2019s disease (characterized by gradual and continuous cognitive decline), vascular dementia (noted for stepwise deterioration), and frontotemporal dementia (which presents primarily with behavioral abnormalities). The first-line pharmacological management of DLB includes cholinesterase inhibitors (like rivastigmine or donepezil) which help improve cognitive symptoms and may also ameliorate hallucinations. Second-line options include cautious use of atypical antipsychotics for severe behavioral disturbances, although patients with DLB are particularly sensitive to these medicines. In pregnancy and lactation, medication risk must be balanced against the severity of symptoms; non-pharmacologic measures and careful monitoring are critical. Option A (DLB) is correct because cognitive fluctuations are a core feature of dementia with Lewy bodies. Options B (Alzheimer\u2019s disease) typically manifest a steady cognitive decline, Option C (FTD) generally presents with prominent personality changes rather than fluctuations, and Option D (Vascular dementia) is characterized by a stepwise decline rather than fluctuating cognition. 1. Look for fluctuating cognition and visual hallucinations when suspecting DLB. 2. Patients with DLB are highly sensitive to neuroleptics. 3. Cholinesterase inhibitors remain the cornerstone of symptomatic treatment for DLB. Recent clinical guidelines emphasize the careful use of cholinesterase inhibitors in DLB, and ongoing research continues to refine diagnostic criteria using biomarkers and advanced imaging techniques. Studies are also examining the role of non-pharmacologic interventions to help manage fluctuations and improve quality of life.",
    "exam_year": "2018",
    "exam_type": "Promotion"
  },
  {
    "question": "young boy, patient with cognitive decline, behavioral changes, has VLCFA:",
    "option_a": "X-linked adrenoleukodystrophy.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "X-linked adrenoleukodystrophy (X-ALD) is an inherited peroxisomal disorder characterized by the accumulation of very long chain fatty acids (VLCFA) in various tissues, including the nervous system and adrenal cortex. X-ALD results from mutations in the ABCD1 gene, which encodes a peroxisomal membrane protein involved in the transport and beta-oxidation of VLCFAs. The resulting accumulation of VLCFAs leads to demyelination, inflammatory changes, and adrenal insufficiency. This process is particularly detrimental to the white matter integrity in the brain. In young boys, X-ALD typically presents with progressive cognitive decline, behavioral changes, and motor dysfunction. The accumulation of VLCFAs is a biochemical hallmark and is used for diagnosis. Additionally, adrenal insufficiency may manifest with hyperpigmentation, hypotension, and salt wasting. The diagnosis is established through biochemical testing showing markedly elevated levels of VLCFAs. MRI often demonstrates symmetrical white matter lesions. Differential diagnoses include other leukodystrophies which may share similar imaging features but do not have the specific biochemical hallmark of VLCFA accumulation. Clinical evaluation for adrenal insufficiency is also essential. The mainstay of treatment in early stages is hematopoietic stem cell transplantation, which may slow disease progression if performed before advanced neurological decline. Dietary interventions such as Lorenzo\u2019s oil have been used with variable success in reducing VLCFA levels. Hormone replacement therapy is required in cases of adrenal insufficiency. In pregnancy and lactation, careful monitoring is necessary if a carrier or affected individual is pregnant, especially regarding hormone replacement therapy and potential genetic counseling considerations. Option A (X-linked adrenoleukodystrophy) is correct because the hallmark finding of increased VLCFA levels in a young boy with progressive neurological and behavioral decline is pathognomonic for this disorder. The other options are not provided and would not correspond to the specific biochemical abnormality described. 1. VLCFA accumulation is key in diagnosing X-ALD. 2. Early intervention, including stem cell transplantation, is critical for better outcomes. 3. Adrenal insufficiency is a common associated finding requiring prompt management. Recent advances include early diagnosis through newborn screening and emerging gene therapy trials. Current guidelines support early intervention and a multidisciplinary approach, with ongoing research aimed at optimizing timing and modalities of stem cell transplantation and gene-based treatments.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "what is suggestive of dominant parietal lobe.",
    "option_a": "Neglect.",
    "option_b": "Finger agnosia",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Dementia",
    "explanation": "The dominant parietal lobe (typically the left hemisphere in right\u2010handed individuals) is responsible for complex functions including language, calculation, and praxis. A classic syndrome associated with lesions in the dominant parietal lobe is Gerstmann syndrome, which comprises finger agnosia, agraphia, left\u2010right disorientation, and acalculia. Lesions affecting the angular gyrus and adjacent areas in the dominant parietal lobe disrupt high-order integration of sensory, motor, and cognitive functions. Finger agnosia specifically reflects impaired neural processing needed to individuate and recognize the position and identity of one\u2019s own fingers. Patients with dominant parietal lobe damage may present with difficulties in performing tasks that require fine motor coordination and in recognizing parts of their own body, while neglect, in contrast, is more often a feature of non\u2010dominant (right) parietal lesions. The workup involves detailed neurological examination and neuropsychological testing. Imaging studies, especially MRI, can help localize lesions in the parietal region. Differential considerations include stroke, neoplasm, or neurodegenerative processes affecting the parietal region. Management is directed toward the underlying cause\u2014whether vascular, neoplastic, or degenerative. In the case of stroke, for example, acute management guidelines including thrombolysis (if in the window period) apply. In all patients, cognitive rehabilitation and occupational therapy play important roles. In pregnancy and lactation, treatment choices (e.g., timing of imaging studies or interventions) are carefully weighed against fetal risks, and non-ionizing imaging (MRI) is preferred when possible. Option B (Finger agnosia) is correct because it is one of the cardinal features of dominant parietal lobe involvement as seen in Gerstmann syndrome. Option A (Neglect) is more indicative of non\u2010dominant right parietal lobe lesions. 1. Gerstmann syndrome is a hallmark of dominant parietal lobe dysfunction. 2. Neglect is classically associated with non\u2010dominant parietal lesions. 3. Neuroimaging is essential in localizing the lesion. Recent studies reinforce the importance of detailed neuropsychological assessments in identifying the specific deficits of parietal lobe lesions, and emerging research is evaluating targeted rehabilitation strategies to improve outcomes in patients with Gerstmann syndrome.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  }
]